Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter to the Editor

A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19)

Author(s): Suraj N. Mali*, Bapu R. Thorat and Atul R. Chopade

Volume 21, Issue 3, 2021

Published on: 10 May, 2020

Page: [311 - 313] Pages: 3

DOI: 10.2174/1871526520666200511005546

[1]
Mali, S.N.; Pratap, A.P.; Thorat, B.R. The Rise of New Coronavirus Infection-(COVID-19): A Recent Update. EJMO, 2020, 4(1), 35-41. [http://dx.doi.org/10.14744/ejmo.2020.22222].
[2]
WHO situation report,. 2020.https://www.who.int/emergencies/ diseases/ novel-coronavirus-2019/situation-reports Last accessed on 07-04-2020
[3]
Veljkovic, V.; Vergara-Alert, J.; Segalés, J.; Paessler, S. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. F1000 Res., 2020, 9(52), 52. [http://dx.doi.org/10.12688/f1000research.22149.2].
[4]
Zhou, P.; Yang, X-L.; Wang, X-G. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in 2 humans and its potential bat origin. bioRxiv, 2020, (January), 23.
[5]
Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends, 2020, 14(1), 69-71. [http://dx.doi.org/10.5582/bst.2020.01020]. [PMID: 31996494].
[6]
Zumla, A.; Chan, J.F.; Azhar, E.I.; Hui, D.S.; Yuen, K.Y. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016, 15(5), 327-347. [http://dx.doi.org/10.1038/nrd.2015.37]. [PMID: 26868298].
[7]
Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)., 2020.
[http://dx.doi.org/10.1038/d41573-020-00016-0]
[8]
Sommerstein, R.; Kochen, M.M.; Messerli, F.H.; Gräni, C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J. Am. Heart Assoc., 2020, 9(7)e016509
[http://dx.doi.org/[http://dx.doi.org/10.1161/JAHA.120.016509].] [PMID: [32233753].]
[9]
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19)—China, 2020. China CDC Wkly., 2020, 2, 113-122.
[10]
Dong, E; Du, H; Gardner, L An interactive web‐based dashboard to track COVID‐19 in real time. Lancet Infect Dis., 2020, S1473‐3099(20), 30120-30121.
[http://dx.doi.org/10.1016/S1473‐3099(20)30120‐1]
[11]
Guo, J.; Huang, Z.; Lin, L.; Lv, J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Am. Heart Assoc., 2020, 9(7)e016219 [http://dx.doi.org/10.1161/JAHA.120.016219]. [PMID: 32233755].
[12]
Malha, L.; Mueller, F.B.; Pecker, M.S.; Mann, S.J.; August, P.; Feig, P.U. COVID-19 and the Renin-Angiotensin System. Kidney Int. Rep., 2020. [http://dx.doi.org/10.1016/j.ekir.2020.03.024].
[13]
https://www.the-scientist.com/news-opinion/blood-pressure-meds-point-the-way-to-possible-covid-19-treatment-67371
[14]
Sanchis-Gomar, F.; Lavie, C.J.; Perez-Quilis, C.; Henry, B.M.; Lippi, G. Angiotensin-Converting Enzyme 2 and Anti- Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19). Mayo Clin. Proc., Elsevier, 2020, 196(6), 1222-1230.
[15]
AlGhatrif, M.; Cingolani, O.; Lakatta, E.G. The Dilemma of Coronavirus Disease Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. JAMA Cardiol., 2020, 5(7), 747-748.
[16]
Hanff, T.C.; Harhay, M.O.; Brown, T.S.; Cohen, J.B.; Mohareb, A.M. There an association between COVID-19 mortality and the renin-angiotensin system—a call for epidemiologic investigations. Clin. Infect. Dis., 2020, 71(15), 870-874.
[17]
Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181, 1-10. [http://dx.doi.org/10.1016/j.cell.2020.02.052]. [PMID: 32142651].
[18]
Hofmann, H.; Geier, M.; Marzi, A.; Krumbiegel, M.; Peipp, M.; Fey, G.H.; Gramberg, T.; Pöhlmann, S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun., 2004, 319(4), 1216-1221. [http://dx.doi.org/10.1016/j.bbrc.2004.05.114]. [PMID: 15194496].
[19]
Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.X.; Wang, Y.Y.; Xiao, G.F.; Shi, Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798), 270-273. [http://dx.doi.org/10.1038/s41586-020-2012-7]. [PMID: 32015507].
[20]
Masuyer, G.; Schwager, S.L.; Sturrock, E.D.; Isaac, R.E.; Acharya, K.R. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci. Rep., 2012, 2, 717. [http://dx.doi.org/10.1038/srep00717]. [PMID: 23056909].
[21]
Imai, Y.; Kuba, K.; Penninger, J.M. The renin–angiotensin system in acute respiratory distress syndrome. Drug Discov. Today Dis. Mech., 2006, 3(2), 225-229. [http://dx.doi.org/10.1016/j.ddmec.2006.06.012].
[22]
Mourad, J.J.; Levy, B.I. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat. Rev. Cardiol., 2020, 17(5), 313. [http://dx.doi.org/10.1038/s41569-020-0368-x]. [PMID: 32231328].
[23]
Zheng, Y.Y.; Ma, Y.T.; Zhang, J.Y.; Xie, X. Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’. Nat. Rev. Cardiol., 2020, 17, 313-314. [http://dx.doi.org/10.1038/s41569-020-0369-9]. [PMID: 32231330].
[24]
Patel, A.B.; Verma, A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA, 2020, 323(18), 1769-1770. [http://dx.doi.org/10.1001/jama.2020.4812]. [PMID: 32208485].
[25]
European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. Published March 13, 2020., 2020. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang[March 20, 2020.];
[26]
American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 Available from: https://professional.heart.org/professional/ScienceNews/ UCM_ 505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp [March 20, 2020.];
[27]
Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, J.J.; Pfeffer, M.A.; Solomon, S.D. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New. Engl. J. Med., 2020, 382, 1653-1659. [http://dx.doi.org/10.1056/NEJMsr2005760].

Rights & Permissions Print Cite
Article Metrics
48
1
© 2024 Bentham Science Publishers | Privacy Policy